How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet.
about
Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic LeukemiaAdvancing the Minimal Residual Disease Concept in Acute Myeloid LeukemiaMinimal residual disease in acute myeloid leukaemiaEnhanced cytotoxicity of natural killer cells following the acquisition of chimeric antigen receptors through trogocytosisThe European LeukemiaNet: achievements and perspectives.CD5 Positive B Lymphoblastic Leukemia: Report of a Case with Review of LiteratureQuantitative detection of the human cervical cancer oncogene for monitoring the minimal residual disease in acute leukemiaSingle molecule quantitation and sequencing of rare translocations using microfluidic nested digital PCR.Asymmetric-detection time-stretch optical microscopy (ATOM) for ultrafast high-contrast cellular imaging in flow.Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10.Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms.Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part IV - postanalytic considerations.Molecular diagnostics, targeted therapy, and the indication for allogeneic stem cell transplantation in acute lymphoblastic leukemia.How to assess minimal residual disease in pediatric and adult acute myeloid leukemia?Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter settingEnhanced sensitivity of flow cytometry for routine assessment of minimal residual disease.Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT.PCR-based amplification of circulating RNAs as prognostic and predictive biomarkers - Focus on neuroblastoma.Guidelines on the use of multicolour flow cytometry in the diagnosis of haematological neoplasms. British Committee for Standards in Haematology.Sequential monitoring of minimal residual disease in acute lymphoblastic leukemia: 7-year experience in a pediatric hematology/oncology unit.Minimal residual disease in acute myeloid leukemia: already predicting a safe haven?
P2860
Q26751269-D081D7AC-465E-4666-8792-5FFAB646D255Q28087291-50BC2FFC-F54B-404F-B3F8-8A700DBF9601Q34179265-1327C4E8-1DD2-4494-849A-B976EBD1EC2AQ34338159-DB9CB844-71E9-451B-9AAC-6D2401F38F97Q34451619-24495446-EEEF-46B4-A5F7-92BDB0A21137Q37048334-AB8EB426-C7B5-4B57-99A0-5EE081EA7FDAQ37070953-575D435D-B7F5-4803-A799-EA1A709B57BAQ37148541-F0AD4620-0F17-4129-AB0C-F12FB70B3B7BQ37466983-4025293C-374C-473F-82E3-763A097CB5F9Q37831107-F72E788E-6655-4773-84E7-46A8E3673075Q37850824-8D89C0E7-624D-47FE-98F0-A5736565CF7AQ38136152-237FD1A9-CA69-423A-8872-88518D9E5EEDQ39112294-2E78B6D6-4030-4A22-A161-824935B23F97Q40033118-88B32AA6-8352-4646-BAC5-B5DC495D34A5Q42585493-97DF6D82-E513-4E1A-8A4E-F10E27FBF4EAQ42832364-97884DE2-43FA-489E-9E11-DA380B415C96Q44919804-E3C7CDA0-632C-4CBC-8CE2-FE4A9C0E2730Q52816741-F6037DB8-AFA5-4B0B-915F-97E8F924A1DCQ53600589-071F75E1-79C9-45CF-838F-16D46FB8E4C3Q54434736-C8DFB188-3204-4CBF-99D1-636BC382E951Q54632366-D1FF3594-6E93-4985-8390-46BD92C1CD19
P2860
How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
How and why minimal residual d ...... of the European LeukaemiaNet.
@en
How and why minimal residual d ...... of the European LeukaemiaNet.
@nl
type
label
How and why minimal residual d ...... of the European LeukaemiaNet.
@en
How and why minimal residual d ...... of the European LeukaemiaNet.
@nl
prefLabel
How and why minimal residual d ...... of the European LeukaemiaNet.
@en
How and why minimal residual d ...... of the European LeukaemiaNet.
@nl
P2860
P1433
P1476
How and why minimal residual d ...... of the European LeukaemiaNet.
@en
P2093
Jaspal S Kaeda
Marie C Béné
P2860
P304
P356
10.3324/HAEMATOL.2008.004267
P577
2009-07-07T00:00:00Z